Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

-Highlights potential uses of Celularity biomaterials in regenerative medicine applications that combine stem cells and biomaterial scaffolds for use in constructing tissues and for cell delivery

-Poster Presentation at the 12th World Biomaterials Congress in Daegu, Republic of Korea

FLORHAM PARK, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced that its abstract “Tri-layer decellularized, dehydrated human amniotic membrane supports proliferation and stemness of limbal stem cells derived from induced pluripotent stem cells” has been accepted as a poster presentation at WBC 2024, the 12th World Biomaterials Congress which will be held on 26-31 May 2024 in Daegu, Republic of Korea, and hosted by the Korean Society for Biomaterials (KSBM). The theme of WBC 2024 is “Convergence in Biomaterials: a vision for the future of healthcare.”

The study described in the poster presentation investigated Celularity’s tri-layer decellularized, dehydrated human amniotic membrane technology product as a carrier of induced pluripotent stem cell derived-limbal stem cells (iPSC-LSC) which were investigated for the treatment of limbal stem cell deficiency (LSCD). LSCD is a debilitating ocular surface disorder that occurs due to loss or dysfunction of limbal stem cells (LSCs) that are vital for the re-population of the corneal epithelium and to the barrier function of the limbus. Limbal Stem Cell (LSC) transplant is a recognized method to restore the ocular surface in advanced stem cell deficient corneas.

Robert J. Hariri, M.D., Ph.D., Celularity Chairman, CEO and Founder, noted, “LSCD is characterized by cellular invasion onto the cornea by conjunctival epithelium, leading to impaired epithelial wound healing and resulting in chronic ocular surface inflammation, neovascularization, and eventually opacification. The causes of LSCD include trauma and contact lens wear as well as infection and inflammation and this represents a significant clinical opportunity for Celularity’s regenerative medicine technologies.” According to data published by Delve Insight, the United States had the highest number of diagnosed prevalent cases of LSCD.